Publikationen 2015
Albers P.
Poor-prognosis germ cell tumours: room for improvement.
Eur Urol. 2015 Mar;67(3):544-5.
doi: 10.1016/j.eururo.2014.11.009. Epub 2014 Nov 20. No abstract available. PMID: 25465972
Albers P.
Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease.
Nat Rev Urol. 2015 Nov;12(11):602-3.
doi: 10.1038/nrurol.2015.219. Epub 2015 Sep 1. No abstract available. PMID: 26334083
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J.
Guidelines on Testicular Cancer: 2015 Update.
Eur Urol. 2015 Dec;68(6):1054-68.
doi: 10.1016/j.eururo.2015.07.044. Epub 2015 Aug 18. PMID: 26297604
Albers P, Heidenreich A.
Radikale Zystoprostatektomie und pelvine Lymphadenektomie.
Aktuelle Urol. 2014 Nov;45(6):490-8.
doi: 10.1055/s-0034-1395577. Epub 2014 Dec 16. German. No abstract available. PMID: 25514780
Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F, Antoch G, Gabbert HE, Albers P, Schimmöller L.
The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.
J Cancer Res Clin Oncol. 2015 Nov;141(11):2061-8.
doi: 10.1007/s00432-015-1991-5. Epub 2015 May 27. PMID: 26013424
Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, Gabbert HE, Becker N, Antoch G, Albers P, Schimmöller L.
Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Eur Urol. 2015 Oct;68(4):713-20.
Arsov C, Rabenalt R, Quentin M, Hiester A, Blondin D, Albers P, Antoch G, Schimmöller L.
Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial.
World J Urol. 2016 Feb;34(2):215-20.
doi: 10.1007/s00345-015-1612-6. Epub 2015 Jun 9. PMID: 26055645
Babaian KN, Okhunov Z, Juncal S, Ordon M, Lusch A, Zand T, Andreoni C, Landman J.
Clinical outcomes of patients with nondiagnostic biopsy during cryoablation of small renal masses.
Urology. 2015 Mar;85(3):605-9.
doi: 10.1016/j.urology.2014.11.016. PMID: 25733273
Decoene J, Winter C, Albers P.
False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Urol Oncol. 2015 Jan;33(1):23.e15-21.
doi: 10.1016/j.urolonc.2014.09.019. Epub 2014 Nov 4. PMID: 25454484
del Junco M, Okhunov Z, Yoon R, Khanipour R, Juncal S, Abedi G, Lusch A, Landman J.
Development and initial porcine and cadaver experience with three-dimensional printing of endoscopic and laparoscopic equipment.
J Endourol. 2015 Jan;29(1):58-62.doi: 10.1089/end.2014.0280. PMID: 24983138
Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX
Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies.
BMC Genomics. 2015 Nov 30;16(1):1019.
doi: 10.1186/s12864-015-2227-4. No abstract available. PMID: 26621286
Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics. 2015 May 22;16:403.
doi: 10.1186/s12864-015-1450-3. Erratum in: BMC Genomics. 2015;16(1):1019. PMID: 25997541
Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T.
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group.
J Clin Oncol. 2016 Feb 1;34(4):345-51.
doi: 10.1200/JCO.2015.62.7000. Epub 2015 Oct 12. PMID: 26460295
Fichtner J, Kowalski C, Wesselmann S, Albers P.
[Indicator analysis of prostate cancer centers certified by the German Cancer Society 2015].
Urologe A. 2015 Nov;54(11):1530, 1532-6.
doi: 10.1007/s00120-015-3855-7. German. PMID: 26573670
Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R; German Testicular Cancer Study Group.
Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours
Eur Urol. 2016 Mar;69(3):518-25.
doi: 10.1016/j.eururo.2015.11.007. Epub 2015 Nov 24. PMID: 26620368
Giessing M.
[Urological follow-up and development of cancer after renal transplantation].
Urologe A. 2015 Oct;54(10):1393-401.
doi: 10.1007/s00120-015-3910-4. German. PMID: 26459582
Goering W, Schmitt K, Dostert M, Schaal H, Deenen R, Mayer J, Schulz WA.
Human endogenous retrovirus HERV-K(HML-2) activity in prostate cancer is dominated by a few loci.
Prostate. 2015 Dec;75(16):1958-71.
doi: 10.1002/pros.23095. Epub 2015 Sep 18. PMID: 26384005
Greife A, Hoffmann MJ, Schulz WA.
Consequences of Disrupted Notch Signaling in Bladder Cancer.
Eur Urol. 2015 Jul;68(1):3-4.
doi: 10.1016/j.eururo.2015.02.034. Epub 2015 Mar 16. PMID: 25791514
Greife A, Tukova J, Steinhoff C, Scott SD, Schulz WA, Hatina J.
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
Tumour Biol. 2015 May;36(5):3293-300.
doi: 10.1007/s13277-014-2959-9. Epub 2015 Jan 8. PMID: 25566959
Hatina J, Kripnerová M, Tuková J, Šrámek J, Dvořák P, Pešta M, Dobrá J, Babuška V, Racek J, Sobol M, Philimonenko A, Hozák P, Czuba Z, Schulz WA, Strell C, Grimm S, Jennek S, Friedrich KH.
[Tumour-stroma interactions in urothelial cancer].
Urologe A. 2015 Apr;54(4):516-25.
doi: 10.1007/s00120-014-3754-3. Review. German. PMID: 25895564
Heubach J, Monsior J, Deenen R, Niegisch G, Szarvas T, Niedworok C, Schulz WA, Hoffmann MJ.
The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.
Mol Cancer. 2015 May 21;14:108.
doi: 10.1186/s12943-015-0371-8. PMID: 25994132
Hidas G, Lee HJ, Bahoric A, Kelly MS, Watts B, Liu Z, Saharti S, Lusch A, Alamsahebpour A, Kerbl D, Truong H, Zi X, Khoury AE.
Aerosol transfer of bladder urothelial and smooth muscle cells onto demucosalized colonic segments for bladder augmentation: in vivo, long term, and functional pilot study.
J Pediatr Urol. 2015 Oct;11(5):260.e1-6.
doi: 10.1016/j.jpurol.2015.02.020. Epub 2015 May 1. PMID: 26022502
Knievel J, Schulz WA, Greife A, Hader C, Lübke T, Schmitz I, Albers P, Niegisch G
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Int J Mol Sci. 2014 Nov 7;15(11):20500-17.
doi: 10.3390/ijms151120500. PMID: 25387078
Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S.
Quality assessment in prostate cancer centers certified by the German Cancer Society.
World J Urol. 2015 Sep 21.
[Epub ahead of print] PMID: 26391484
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ.
Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
Clin Genitourin Cancer. 2015 Oct 24. pii: S1558-7673(15)00261-X.
doi: 10.1016/j.clgc.2015.10.005. [Epub ahead of print] PMID: 26589729
Lorch A.
A practice-changing step forward in germ-cell cancer?
Lancet Oncol. 2014 Dec;15(13):1409-10.
doi: 10.1016/S1470-2045(14)71103-9. Epub 2014 Nov 13. No abstract available. PMID: 25456352
Lusch A, Okhunov Z, del Junco M, Yoon R, Khanipour R, Menhadji A, Landman J.
Comparison of optics and performance of single channel and a novel dual-channel fiberoptic ureteroscope.
Urology. 2015 Jan;85(1):268-72.
doi: 10.1016/j.urology.2014.09.032. PMID: 25530400
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G.
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Clin Genitourin Cancer. 2015 Apr;13(2):178-84.
doi: 10.1016/j.clgc.2014.08.010. Epub 2014 Sep 23. PMID: 25450035
Niegisch G, Hoffmann MJ, Koutsogiannouli EA, Schulz WA.
[Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options].
Urologe A. 2015 Apr;54(4):526-32.
doi: 10.1007/s00120-014-3756-1. German. PMID: 25784269
Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P.
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
Oncology. 2015;89(2):70-8.
doi: 10.1159/000376551. Epub 2015 Mar 11. PMID: 25765871
Nüsgen N, Goering W, Dauksa A, Biswas A, Jamil MA, Dimitriou I, Sharma A, Singer H, Fimmers R, Fröhlich H, Oldenburg J, Gulbinas A, Schulz WA, El-Maarri O.
Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs.
Clin Epigenetics. 2015 Mar 1;7(1):17.
doi: 10.1186/s13148-015-0051-y. eCollection 2015. PMID: 25798207
Ohlmann CH, Albers P, Boehm K, Graefen M, Hakenberg OW, Kuczyk M, Graf J, Peters I, Protzel C.
[Follow-up of urological tumor treatment].
Urologe A. 2015 Sep;54(9):1223-33.
doi: 10.1007/s00120-015-3936-7. German. PMID: 26246111
Ohlmann CH, Duensing S, Eichenauer R, König F, Machtens S, Schostak M, Thomas C, Albers P.
[Metastasized prostate cancer. Position paper on the use of chemotherapy].
Urologe A. 2015 Jul;54(7):998-1001.
doi: 10.1007/s00120-015-3841-0. German. PMID: 25962469
Oing C, Lorch A, Bokemeyer C, Honecker F, Beyer J, Berger LA, Oechsle K.
First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.
J Cancer Res Clin Oncol. 2015 May;141(5):923-31.
doi: 10.1007/s00432-014-1876-z. Epub 2014 Nov 14. PMID: 25395217
Okhunov Z, Juncal S, Ordon M, George AK, Lusch A, del Junco M, Nguyentat M, Lobko II, Kavoussi L, Landman J.
Comparison of outcomes in patients undergoing percutaneous renal cryoablation with sedation vs general anesthesia.
Urology. 2015 Jan;85(1):130-4.
doi: 10.1016/j.urology.2014.09.013. Epub 2014 Nov 14. PMID: 25440762
Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruš D, Rosti G, Stephenson AJ, Tandstad T; On behalf of: SWENOTECA (Swedish Norwegian Testicular Cancer group), the Italian Germ Cell Cancer Group (IGG), Spanish Germ Cell Cancer Group (SGCCG).
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Ann Oncol. 2015 May;26(5):833-8.
doi: 10.1093/annonc/mdu514. Epub 2014 Nov 6. Review. PMID: 25378299
Pixberg CF, Schulz WA, Stoecklein NH, Neves RP.
Characterization of DNA Methylation in Circulating Tumor Cells.
Genes (Basel). 2015 Oct 21;6(4):1053-75.
doi: 10.3390/genes6041053. Review. PMID: 26506390
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G.
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Clin Genitourin Cancer. 2015 Feb;13(1):71-9.
doi: 10.1016/j.clgc.2014.06.004. Epub 2014 Jun 9. PMID: 24993933
Putz J, Giessing M, Fornara P, Stöckle M, Friedersdorff F, Dreikorn K, Heynemann H, Wunderlich H, Stein K, Protzel C, Hakenberg OW.
[The 22nd annual meeting of the working group for kidney transplantation of the German Society of Urology in Rostock].
Urologe A. 2015 Oct;54(10):1429-32.
doi: 10.1007/s00120-015-3948-3. German. No abstract available. PMID: 26459583
Rezaei M, Emadi-Baygi M, Hoffmann MJ, Schulz WA, Nikpour P.
Altered expression of LINC-ROR in cancer cell lines and tissues.
Tumour Biol. 2015 Aug 28. [Epub ahead of print]
PMID: 26314857
Schneider AT, Albers P, Müller-Mattheis V.
E-Learning in Urology: Implementation of the Learning and Teaching Platform CASUS® - Do Virtual Patients Lead to Improved Learning Outcomes? A Randomized Study among Students.
Urol Int. 2015;94(4):412-8.
doi: 10.1159/000368653. Epub 2015 Apr 10. PMID: 25871786
Schulz WA, Koutsogiannouli EA, Niegisch G, Hoffmann MJ.
Epigenetics of urothelial carcinoma.
Methods Mol Biol. 2015;1238:183-215.
doi: 10.1007/978-1-4939-1804-1_10. Review. PMID: 25421661
Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C.
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Urol Oncol. 2016 Apr;34(4):168.e21-8.
doi: 10.1016/j.urolonc.2015.11.007. Epub 2015 Dec 11. PMID: 26699830
Skowron MA, Niegisch G, Fritz G, Arent T, van Roermund JG, Romano A, Albers P, Schulz WA, Hoffmann MJ.
Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.
J Exp Clin Cancer Res. 2015 Nov 25;34:144.
doi: 10.1186/s13046-015-0259-x. PMID: 26606927
Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J.
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Eur Urol. 2016 Apr;69(4):634-41.doi: 10.1016/j.eururo.2015.07.042. Epub 2015 Aug 8. PMID: 26264159
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J.
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Clin Genitourin Cancer. 2015 Apr;13(2):185-92.
doi: 10.1016/j.clgc.2014.09.004. Epub 2014 Oct 2. PMID: 25458370
Steffens J, Kranz J, Albers P.
[Improved prostate cancer treatment in certified centers : Is the strategic vision realistic?].
Urologe A. 2015 Nov;54(11):1515-6.
doi: 10.1007/s00120-015-3835-y. German. No abstract available. PMID: 26573668
Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Lancet Oncol. 2015 Jan;16(1):76-86.
doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11. PMID: 25498218
Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A.
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.
Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43.
doi: 10.1016/j.critrevonc.2015.05.014. Epub 2015 Jun 5. Review. PMID: 26092320